Could a daily pill replace insulin for kidney transplant patients?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Written informed consent obtained before any trial-related procedures are performed 2. Male or female; age: 18-80 years 3. Diagnosis of post-transplant hyperglycaemia 10 to 40 days after transplantation: Fasting plasma glucose ≥ 7.0 mmol/L or an oral glucose tolerance test with at plasma glucose ≥ 11.1 mmol/L or Pre-transplant type 2 diabetes: Receiving glucose-lowring treatment prior to kidney transplantation 4. An eGFR \> 15 ml/min/1.73 m2 10 to 40 days after renal transplantation 5. Subject must be willing and able to comply with trial protocol Exclusion Criteria: 1. Type 1 diabetes 2. Dialysis 3. High risk immunological transplantation (not including ABO-incompatible or re-transplantation) 4. Early graft rejection (all rejections verified by biopsy, except borderline rejections. Study initiations can begin 5 days after last dose of rejection treatment with methylprednisolone) 5. Chronic pancreatitis/previous acute pancreatitis 6. Known or suspected hypersensitivity to trial or related products 7. Use of DPP-4 inhibitors within five days prior to screening 8. Use of GLP-1RA within 10 days prior to screening 9. Malignancy (except basal cell carcinoma) 10. Inflammatory bowel disease 11. Previous bowel resection 12. Cardiac disease defined as decompensated heart failure (New York Heart Association class III-IV) and/or diagnosis of unstable angina pectoris and/or myocardial infarction within the last six months 13. Any acute condition or exacerbation of chronic condition that would in the investigator's opinion interfere with the initial trial visit schedule and procedures. 14. Females of childbearing potential who are pregnant, breast-feeding, intend to become pregnant, or are not using adequate contraceptive methods 15. Impaired liver function (plasma ALAT \> two times upper reference levels) 16. Elevated amylase (plasma amylase \> two times upper reference levels) 17. Untreated proliferative diabetic retinopathy, untreated diabetic macular edema or active conditions of this type that are not under therapeutic control according 18. Any condition that clinically significantly impairs the observation of the fundus or anterior chamber